Early Manifest Glaucoma Trial (EMGT)

This study is ongoing, but not recruiting participants.

First Received: September 23, 1999 Last Updated: June 23, 2005 History of Changes

Sponsored by:	National Eye Institute (NEI)
Information provided by:	National Eye Institute (NEI)
ClinicalTrials.gov Identifier:	NCT00000132

Purpose

The primary purpose is to compare the effect of immediate therapy to lower the intraocular pressure (IOP) versus late or no treatment on the progression of newly detected open-angle glaucoma, as measured by increasing visual field loss and/or optic disc changes.

The secondary purposes are to determine the extent of IOP reduction attained by treatment, to explore factors that may influence glaucoma progression, and to describe the natural history of newly detected glaucoma.

Condition	Intervention	Phase
Open-Angle Glaucoma	Drug: Betaxolol Procedure: Argon Laser Trabeculoplasty	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized

Resource links provided by NLM:

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Betaxolol Betaxolol hydrochloride

U.S. FDA Resources

Further study details as provided by National Eye Institute (NEI):

Study Start Date:

October 1992

Show Detailed Description

Eligibility

Ages Eligible for Study:	50 Years to 80 Years
Genders Eligible for Study:	Both

Criteria

Men and women between ages 50 and 80 years who have newly detected and untreated chronic open-angle glaucoma with repeatable visual field defects by Humphrey perimetry are eligible for inclusion. Exclusion criteria include the following: advanced visual field loss (MD less than or equal to 16 dB) or threat to fixation; mean IOP > 30 mm Hg or any IOP > 35 mm Hg in at least one eye; VA < 0.5 in either eye; or any conditions precluding reliable fields or photos, use of study treatment, or 4-year followup.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000132

Locations

Sweden
Department of Ophthalmology, Malmo University Hospital, University of Lund
Malmo, Sweden
Department of Ophthalmology, Helsingborg Hospital
Helsingborg, Sweden

Sponsors and Collaborators

National Eye Institute (NEI)

More Information

No publications provided

Study ID Numbers:	NEI-31
Study First Received:	September 23, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00000132 History of Changes
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Neurotransmitter Agents
Betaxolol
Adrenergic Agents
Eye Diseases
Cardiovascular Agents
Antihypertensive Agents
Glaucoma

Glaucoma, Open-Angle
Adrenergic beta-Antagonists
Adrenergic Antagonists
Peripheral Nervous System Agents
Ocular Hypertension
Hypertension

Additional relevant MeSH terms:

Neurotransmitter Agents
Sympatholytics
Molecular Mechanisms of Pharmacological Action
Betaxolol
Adrenergic Agents
Eye Diseases
Physiological Effects of Drugs
Cardiovascular Agents
Antihypertensive Agents

Pharmacologic Actions
Glaucoma
Autonomic Agents
Therapeutic Uses
Glaucoma, Open-Angle
Adrenergic beta-Antagonists
Adrenergic Antagonists
Peripheral Nervous System Agents
Ocular Hypertension

ClinicalTrials.gov processed this record on July 06, 2009